Lastly, given the single-nucleotide variation difference between APOE3 and APOE4 (Fig. 1), genome editing by CRISPR/Cas9, similar to applications in other neurological diseases (reviewed in [62, 212]), could offer novel opportunities for the study of APOE4-mediated pathogenetic mechanisms [44]. Here, APOE is linked to nervous system disorder.